Search
for
Sort by
Research 841–870 of 1000+
- Design, synthesis and biological evaluation of novel androst-3,5-diene-3-carboxylic acid derivatives as inhibitors of 5α-reductase type 1 and 2
- The Modulation of Aromatase and Estrogen Receptor Alpha in Cultured Human Dermal Papilla Cells by Dexamethasone: A Novel Mechanism for Selective Action of Estrogen via Estrogen Receptor Beta?
- Photobiomodulation for the management of alopecia: mechanisms of action, patient selection and perspectives
- Activity of 17β-(N-Alkyl/arylformamido) and 17β-[(N-Alkyl/aryl) alkyl/arylamido]-4-methyl-4-aza-5α-androstan-3-ones as 5α-Reductase Inhibitors in the Hamster Flank Organ and Ear11The research has been supported by Endorecherche that is seeking patent protection for the new compounds. F. Labrie is President of Endorecherche.
- Comparison of pemetrexed and docetaxel as salvage chemotherapy for the treatment for nonsmall-cell lung cancer after the failure of epidermal growth factor receptor-tyrosine kinase inhibitors
- Hair Growth-Promoting Effects of a Multi-Targeted Cosmetic Formulation Containing PYGL, DP2, and 15-PGDH Inhibitors Developed Using AI-Based DeepZema® in Androgenetic Alopecia: A 24-Week Randomized Controlled Trial
- Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2
- 32237 Clinician and patient evaluation of improvement for eyebrow and eyelashes hair loss during baricitinib phase 3 trials BRAVE-AA1 and BRAVE-AA2
- Treatment of moderate-to-severe alopecia areata in adolescents with baricitinib: A retrospective review of 29 patients
- 54022 Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata
- The use of topical ruxolitinib 1.5% cream in frontal fibrosing alopecia: A case report
- LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
- The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1
- Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
- 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- Upadacitinib for management of recalcitrant alopecia areata: A retrospective case series
- 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
- Multiomic Characterization of Treatment Response to JAK Inhibition in Patients with APECED
- Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
- A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- Medikamentöse Therapie der BPH Ist eine Kombinationstherapie mit 5α-Reduktasehemmern und α-Rezeptorenblockern sinnvoll?
- Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives
- Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata
- Successful treatment of severe diffuse alopecia areata with abrocitinib
- 700 Tyrosine kinase 2 inhibition rescues hair follicles from IL-12–mediated immune privilege collapse and reverses the induction of human alopecia areata in a humanized mouse model
- Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
- Trazodone associated with Clomiphene a proposal treatment for post finasteride syndrome
- Sorafenib-Associated Facial Acneiform Eruption
- Women With Polycystic Ovary Syndrome: A Review of Susceptibility to Type 2 Diabetes